KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Interest Expenses (2019 - 2025)

Historic Interest Expenses for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to $22.1 million.

  • Esperion Therapeutics' Interest Expenses rose 4620.74% to $22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.4 million, marking a year-over-year increase of 3542.13%. This contributed to the annual value of $59.3 million for FY2024, which is 46.63% up from last year.
  • As of Q3 2025, Esperion Therapeutics' Interest Expenses stood at $22.1 million, which was up 4620.74% from $20.5 million recorded in Q2 2025.
  • Esperion Therapeutics' Interest Expenses' 5-year high stood at $22.1 million during Q3 2025, with a 5-year trough of $8.1 million in Q1 2021.
  • Moreover, its 5-year median value for Interest Expenses was $14.3 million (2022), whereas its average is $14.9 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Interest Expenses skyrocketed by 17706.98% in 2021, and later crashed by 559.95% in 2024.
  • Esperion Therapeutics' Interest Expenses (Quarter) stood at $13.4 million in 2021, then increased by 6.69% to $14.3 million in 2022, then rose by 5.08% to $15.1 million in 2023, then rose by 9.07% to $16.4 million in 2024, then soared by 34.28% to $22.1 million in 2025.
  • Its Interest Expenses stands at $22.1 million for Q3 2025, versus $20.5 million for Q2 2025 and $19.4 million for Q1 2025.